It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Medical Information Request
Medical Information Request

 

 

Our commitment to
ongoing communication
on safety

A verified up-to-date global source of safety
information from clinical trials and
post-marketing experience with
ofatumumab for Healthcare Professionals

Website full content update:
July 2022

 

Latest Updates:  November 2022

 


As of 25 Sep 2022, a total of approximately 3,020 patients with relapsing multiple sclerosis (RMS) received ofatumumab in clinical trials including the ongoing open-label extension and there was approximately 37,127 patient-years post marketing experience1

Clinical_Trials_and_Post_Marketing
Hone_Image_Button

Report an adverse event

 
References
1. Data on File. Periodic Safety Update Report (Cut-off date: 25 Sep 2022); Novartis Pharma AG